Related Experiment Video
Updated: Feb 25, 2026
Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
Published on: December 19, 2020
Conjugate pneumococcal vaccines for non-indigenous children in Australia
1National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, New Children's Hospital, Sydney, NSW. peterm@nch.edu.au
Insights
A new pneumococcal vaccine for children will be available in Australia. Its inclusion on the national schedule requires evaluating disease burden, serotypes, and cost-effectiveness.
Area of Science:
- Pediatrics
- Immunology
- Public Health
Background:
- Childhood pneumococcal disease causes significant illness and death.
- Measuring the total burden of pneumococcal disease is challenging.
- Haemophilus influenzae type b (Hib) invasive disease burden is better quantified.
Purpose of the Study:
- To inform the inclusion of a new pneumococcal vaccine on the Australian Standard Vaccination Schedule.
- To assess the cost-effectiveness of the pneumococcal vaccine.
- To guide postmarketing surveillance strategies.
Main Methods:
- Analysis of childhood pneumococcal disease burden in Australia.
- Evaluation of pneumococcal serotype distribution in Australian children.
- Cost-effectiveness analysis of the seven-valent conjugate pneumococcal vaccine.
Main Results:
- A seven-valent conjugate pneumococcal vaccine will be available in Australia by early 2001.
- The vaccine is expected to be indicated for high-risk groups and privately purchased.
- Further data on disease burden, serotype distribution, and cost-effectiveness are needed.
Conclusions:
- Consideration of pneumococcal disease burden and vaccine cost-effectiveness is crucial for national scheduling.
- Postmarketing surveillance will be essential for monitoring vaccine impact.
- The introduction of the pneumococcal vaccine necessitates a comprehensive evaluation.
Abstract:
Childhood pneumococcal disease is associated with substantial morbidity and mortality, but total disease burden is more difficult to measure than for invasive disease caused by Haemophilus influenzae type b (Hib). A safe, effective seven-valent conjugate pneumococcal vaccine will be available in Australia by early 2001, and will certainly be indicated for high-risk groups and purchased in the private sector, as was Hib vaccine. The status of this vaccine on the Australian Standard Vaccination Schedule will require more detailed consideration of the burden and serotype distribution of pneumococcal disease in Australian children and the vaccine's likely cost-effectiveness. Postmarketing surveillance will be particularly important.
Related Concept Videos
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:30Pneumonia III: Complications and Assessment
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:51Vaccinations
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...